Solid Biosciences Inc. operates as a biotechnology company. The Company develops therapies and devices for the patients with duchenne muscular dystrophy. Solid Biosciences serves clients in the United States.

Current Report (Form 8-K | Period ending 2025-11-03)

Quarterly Report (Form 10-Q | Period ending 2025-09-30)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Solid Biosciences (SLDB US)

Current Report (Form 8-K | Period ending 2025-11-03)

Quarterly Report (Form 10-Q | Period ending 2025-09-30)

Quarterly Report (Form 10-Q | Period ending 2025-06-30)

Current Report (Form 8-K | Period ending 2025-06-12)

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)